Innoviva Q2 Revenue Jumps 19% on 46% IST Sales Surge, Guides $150M+ for 2026
INVA sits 25% above its 52-week low of $16.52.
Summary
Innoviva's Q2 revenue climbed 19% year-over-year, driven by a 46% surge in IST net product sales, with U.S. sales up 26%. Royalty revenue from GSK respiratory products held steady at $59.8 million. The company posted a net loss of $83.42 million, primarily from a decline in the fair value of equity investments, not operational weakness. Management initiated a $31.4 million share buyback and launched the Nortiva Bio unit to advance its long-acting oral drug delivery platform. Full-year 2026 IST U.S. net product sales are guided to at least $150 million, signaling confidence in commercial momentum. This follows a strong Q1 turnaround reported in May, reinforcing a growth trajectory in the core product portfolio.
At the time of this announcement, INVA was trading at $20.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.52 to $25.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.